Trial Profile
To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs SPH 3127 (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
- 11 Nov 2021 Status changed from recruiting to completed.
- 01 Nov 2019 Status changed from not yet recruiting to recruiting.
- 01 Nov 2019 Planned End Date changed from 31 Jan 2020 to 30 Jun 2020.